Zydus Lifesciences Limited
Quant Mutual Fund entered Zydus Lifesciences, acquiring 1,48,47,839 shares representing a 1.49% stake. The position was built through a rights issue.
A vertically integrated pharmaceutical company, Zydus Lifesciences develops, manufactures, and markets generic drugs, specialty pharmaceuticals, and biologics for domestic and international markets. The company operates across multiple therapeutic areas including cardiology, gastroenterology, oncology, and immunology. It serves patients globally through its extensive distribution network, research capabilities, and commitment to addressing unmet healthcare needs across diverse populations and geographies.
Built a quantitative, data-driven investment philosophy in an industry dominated by discretionary stock pickers. Manages over Rs 1.2 lakh crore. Founded by Sanjeev Sharma, Quant MF uses VLRT (Valuation, Liquidity, Risk, and Time) framework to run high-turnover, tactically active portfolios. Grew from obscurity to one of India's top-15 AMCs in under five years, attracting both retail capital and scrutiny for its aggressive churn.